

## Supporting Information

### **Ionizable Lipid Nanoparticles Enhance Lung-Delivery of Gold Nanocluster for Improving Acute Lung Injury Alleviation**

Yongning Bian,<sup>‡[a](#)</sup> Yanggege Li,<sup>‡[a](#)</sup> Dongfang Xia,<sup>a</sup> Yuanyu Huang,<sup>b</sup> Xueyun Gao,<sup>a</sup> Dongdong Su,<sup>\*[a](#)</sup> and Qing Yuan,<sup>\*[a](#)</sup>

<sup>a</sup>Center of Excellence for Environmental Safety and Biological Effects, Department of Chemistry, Beijing University of Technology, Beijing 100124, P. R. China.


<sup>b</sup>School of Life Science, Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Beijing 100081, P. R. China.

E-mail: chmsudd@bjut.edu.cn, yuanqing@bjut.edu.cn


‡These authors contributed equally to this work.

**Table S1** Compositions and proportion of iLNPs.


Component	MW	w/w
Ionizable lipid	967	33.4%
DSPC	790.2	6.1%
Cholesterol	386.7	14.9%
DMG-PEG2000	2538	4.1%
DOTAP	698.6	41.6%




**Figure S1.** (A) The hydrodynamic diameter distribution of GA. (B) The excitation and emission fluorescence spectra of GA.




**Figure S2.** The structure of the ionizable lipid.




**Figure S3.** (A) Physicochemical property characterization of iLNP before and after GA encapsulation, which includes the size, PDI and zeta potential. (B) The PDI of GA@iLNP at different times after preparation.




**Figure S4.** The biodistribution of a single dose of GA (5 mg/kg) and GA@iLNP (containing GA 5 mg/kg) injected intravenically (*i.v.*) in BALB/c mice was compared.




**Figure S5.** The UV absorption (A) and fluorescence spectra (B) of  $\text{CySO}_3^-$ .



**Figure S6.** *In vivo* distribution of intravenously injected lung-targeted iLNP. (A) *In vivo* and *ex vivo* fluorescence imaging after intravenous injection of the fluorescent nanoprobe CySO<sub>3</sub>-@iLNP (100 μM, 100 μL). (B) The Au content distribution in lungs after *i.v.* injection of GA@iLNP (contained GA 5 mg/kg).



**Figure S7.** (A) The experimental protocol for long-term safety monitoring and (B) organ coefficient statistics of each group. Data are presented as means ± SD, n = 3.



**Figure S8.** (A) The body weight of each group was compared: Control, LPS, LPS + GA, LPS + GA@iLNP. Data are presented as means  $\pm$  SD, n = 5. (B) The organ coefficients of major organs from each group. Data are presented as means  $\pm$  SD, n = 5. (C) The lung coefficients from control and GA or GA@iLNP treated normal mice. (D) HE staining of major organs from LPS + GA and LPS + GA@iLNP treated groups.

**Table S2** Blood cell indexes of mice treated with GA@iLNP (mean values ± SD, n=3).

Parameter	Short name	Ctrl	day 4	day 8	day 12	Unit	Reference value range
White blood cell count	WBC	3.59±0.37	2.74±0.11	3.54±0.49	3.27±0.54	10 <sup>9</sup> /L	0.80 - 10.60
Neutrophil count	Neu#	0.72±0.06	0.68±0.09	0.63±0.14	0.76±0.15	10 <sup>9</sup> /L	0.23 - 3.60
Lymphocyte count	Lym#	2.78±0.34	1.97±0.13	2.83±0.39	2.4±0.39	10 <sup>9</sup> /L	0.60 - 8.90
Monocytes count	Mon#	0.067±0.01	0.05±0.008	0.053±0.026	0.073±0.068	10 <sup>9</sup> /L	0.04 - 1.40
Eosinophil granulocyte count	Eo s#	0.02±0.01	0.04±0.03	0.017±0.004	0.033±0.004	10 <sup>9</sup> /L	0.00 - 0.51
Basophil granulocyte count	Bas#	0	0	0	0	10 <sup>9</sup> /L	0.00 - 0.12
Percentage of neutrophil	Neu%	20±1.5	24.7±3.56	17.77±2.45	22.97±0.82	%	6.5 - 50.0
Percentage of lymphocyte	Lym%	77.33±1.73	71.7±2.77	80.13±3.24	73.5±1.87	%	40.0 - 92.0
Percentage of monocytes	Mon%	1.97±0.55	2.03±0.26	1.533±0.76	2.33±1.96	%	0.9 - 18.0
Percentage of eosinophil granulocyte	Eos%	0.67±0.3	1.57±0.94	0.57±0.09	1.2±0.45	%	0.0 - 7.5
Percentage of Basophil granulocyte	Bas%	0.03±0.04	0	0	0	%	0.0 - 1.5
Red blood cell count	RBC	12.3±0.3	11.92±0.47	12.29±0.28	10.36±2.17	10 <sup>12</sup> /L	6.50 - 11.50
Hemoglobin	HGB	199±3.56	191±9.27	196.33±2.35	169.67±35.6	g/L	110 - 165
Hematocrit	HCT	55.47±0.68	53.37±2.52	55.53±1.45	48.07±9.5	%	35.0 - 55.0
Mean corpuscular volume	MCV	45.1±0.8	44.73±0.45	45.17±0.66	46.47±1.71	fL	41.0 - 55.0
Mean hemoglobin content of red blood cells	MCH	16.2±0.32	16±0.21	15.97±0.26	16.37±0.6	pg	13.0 - 18.0
Mean concentration of red blood cell hemoglobin	MCHC	359.33±1.69	358.33±2.05	353.33±4.78	352.67±4.78	g/L	300 - 360
Coefficient of variation of red blood cell distribution width	RDW-CV	14.3±0.21	15.73±1.39	15.03±0.82	14.1±0.163	%	12.0 - 19.0
Standard deviation of red blood cell distribution width	RDW-SD	29.03±0.83	31.53±2.52	30.4±2.11	28.931.18	fL	23.0 - 39.0
Platelet count	PLT	572.33±34.99	579±114.5	836.33±198.5	458.33±45.06	10 <sup>9</sup> /L	400 - 1600
Mean platelet volume	MPV	5.9±0.37	5.93±0.2	6.13±0.25	6.37±0.3	fL	4.0 - 6.2
Width of platelet distribution	PDW	16.9±0.16	16.47±0.25	16.63±0.33	16.6±0.22	fL	12.0 - 17.5
Thrombocytopenia	PCT	0.337±0.001	0.347±0.08	0.509±0.1	0.294±0.04	%	0.100 - 0.780

**Table S3** Biochemical indexes of mice treated with GA@iLNP (mean values ± SD, n=3).

Parameter	Short name	Ctrl	day 4	day 8	day 12	Unit	Reference value range
Alanine aminotransferase	ALT	29.4±3.3	31.1±1.37	33.4±1.4	34.7±4.1	U/L	10.06-96.47
Aspartate aminotransferase	AST	87.9±13.51	91.1±9.89	89.3±3.0	72.9±4.53	U/L	36.31-235.48
Alkaline phosphatase	ALP	184.3±9.29	121±3.86	133.9±7.39	131.3±17.9	U/L	22.52-474.35
Urea nitroge	BUN	7.5±0.51	6.8±0.55	8.03±0.64	7.01±0.13	mmol/L	10.81-34.74
Creatinine	CREA	16.7±3.18	17.8±3.31	14.7±0.49	14.3±1.63	µmol/L	10.91-85.09